Major Shareholding Notification • May 23, 2019
Major Shareholding Notification
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 0440A
Mereo BioPharma Group plc
23 May 2019
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PDMR and Director Dealing
London, May 23, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on May 21, 2019, Peter Bains, Director of Mereo, purchased 47,500 ordinary shares at a price of GBP0.90 per share. Peter also purchased 778 American Depositary Shares (ADSs) at a price of USD4.92 per share.
In addition, on May 22, 2019, John Richard, Head of Corporate Development at Mereo, purchased 3000 ADSs at a price of USD4.90 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1
Details of the person discharging managerial responsibilities
a)
Name
Peter Bains
2
Reason for the notification
a)
Position/status
Director
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mereo BioPharma Group plc
b)
LEI
213800U8JQHIJOS5AS09
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH
b)
Nature of the transaction
PURCHASE
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| GBP0.90 | 47,500 |
d)
Aggregated information: volume, Price
Aggregated volume: 47,500
Aggregated price: GBP0.90
e)
Date of the transaction
2019-05-21
f)
Place of the transaction
AIMX
1
Details of the person discharging managerial responsibilities
a)
Name
Peter Bains
2
Reason for the notification
a)
Position/status
Director
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mereo BioPharma Group plc
b)
LEI
213800U8JQHIJOS5AS09
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
b)
Nature of the transaction
PURCHASE of ADS
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| USD4.92 | 778 |
d)
Aggregated information: volume, Price
Aggregated volume: 778
Aggregated price: USD4.92
e)
Date of the transaction
2019-05-21
f)
Place of the transaction
XNMS
1
Details of the person discharging managerial responsibilities
a)
Name
John Richard
2
Reason for the notification
a)
Position/status
Head of Corporate Development
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Mereo BioPharma Group plc
b)
LEI
213800U8JQHIJOS5AS09
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
b)
Nature of the transaction
PURCHASE of ADS
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| USD4.90 | 3000 |
d)
Aggregated information: volume, Price
Aggregated volume: 3000
Aggregated price: USD4.903
e)
Date of the transaction
2019-05-22
f)
Place of the transaction
XNMS
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHEXLFLKEFBBBD
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.